Provided by Tiger Trade Technology Pte. Ltd.

iShares Biotechnology ETF

203.34
+0.24000.12%
Pre-market: 201.85-1.4900-0.73%05:53 EDT
Volume:1.48M
Turnover:301.21M
Market Cap:10.45B
PE:32.22
High:205.81
Open:201.84
Low:201.12
Close:203.10
52wk High:217.12
52wk Low:149.09
Shares:51.40M
Float Shares:51.40M
Volume Ratio:0.77
T/O Rate:2.87%
Dividend:0.35
Dividend Rate:0.17%
EPS(TTM):6.31
EPS(LYR):35.34
ROE:24.54%
ROA:0.10%
PB:1.28
PE(LYR):5.75

Loading ...

Argenx Shares Plunge After Autoimmune-Disease Trial Halt

Dow Jones
·
40 mins ago

Argenx to Discontinue Late-Stage Sjogren's Disease Trial; Shares Down Pre-Bell

MT Newswires Live
·
1 hour ago

Sino Biopharmaceutical Stock Slides 3.3% in Hong Kong

Dow Jones
·
2 hours ago

U.S. Futures Sink, European Stocks Down

Dow Jones
·
3 hours ago

Newron presses on with Evenamide Phase 3 as FDA halts U.S. arm over safety signal

TIPRANKS
·
4 hours ago

Newron presses on with ENIGMA-TRS program as FDA clinical hold prompts safety review

TIPRANKS
·
5 hours ago

Amgen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
14 hours ago

Moderna Inc. Stock Rises 4.8%, Outperforms Peers

Dow Jones
·
14 hours ago

Vertex to Report Q3 2026 Financial Results, Host Conference Call and Webcast

Reuters
·
14 hours ago

NASDAQ Top and Bottom Performing Stocks at About 02:45 P.m. EDT on 2026-10-07

Reuters
·
15 hours ago

Sector Update: Healthcare

MT Newswires Live
·
17 hours ago

Exchange-Traded Funds Lower as US Equities Decline After Midday

MT Newswires Live
·
17 hours ago

Amgen Inc Stock (AMGN) Moved Up by 3.06% on Oct 7: A Full Analysis

TradingKey
·
18 hours ago

Novartis announces FDA approval of Rhapsido for symptomatic dermographism

TIPRANKS
·
Yesterday

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

GlobeNewswire
·
Yesterday

European Equities Traded in US as ADRs Fall in Wednesday Trading

MT Newswires Live
·
Yesterday

Regeneron Pharma Price Target Raised to $779.00/Share from $758.00 by Morgan Stanley

Dow Jones
·
Yesterday

Amgen is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
Yesterday

Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX)

TIPRANKS
·
Yesterday

Early notable gainers among liquid option names on October 7th

TIPRANKS
·
Yesterday